Clinical Trial

18F-mFBG Cardiac Uptake With Lewy Body Dementia

Study acronym: IRP101-231
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-30 -> 2026-10-30 2026-07-02
minor Completion pushed: 2026-10-30 -> 2026-12-30 2026-07-02
Trial Details
NCT Number NCT07176286
Lead Sponsor Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Conditions Parkinson Disease (PD), Lewy Body Dementia (LBD)
Enrollment 20 participants
Start Date 2026-04-30
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-01